These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 17638937)

  • 1. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
    Manganiello V
    Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
    Medvedeva MV
    Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDE inhibitors: a new approach to treat metabolic syndrome?
    Lugnier C
    Curr Opin Pharmacol; 2011 Dec; 11(6):698-706. PubMed ID: 22018840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase inhibitors.
    Boswell-Smith V; Spina D; Page CP
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic nucleotide phosphodiesterase activities of the embryonic chick ovary.
    Teng CT; Buchler B; Teng CS
    Gen Comp Endocrinol; 1981 Aug; 44(4):409-17. PubMed ID: 6167486
    [No Abstract]   [Full Text] [Related]  

  • 9. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.
    Nagendran J; Archer SL; Soliman D; Gurtu V; Moudgil R; Haromy A; St Aubin C; Webster L; Rebeyka IM; Ross DB; Light PE; Dyck JR; Michelakis ED
    Circulation; 2007 Jul; 116(3):238-48. PubMed ID: 17606845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotide phosphodiesterase in heart and aorta of spontaneously hypertensive rats.
    Sharma RV; Bhalla RC
    Biochim Biophys Acta; 1978 Oct; 526(2):479-88. PubMed ID: 214127
    [No Abstract]   [Full Text] [Related]  

  • 11. Measurements of cyclic AMP and cyclic GMP phosphodiesterase activity in isolated tubular segments.
    Jackson BA; Edwards RM; Dousa TP
    Kidney Int; 1980 Oct; 18(4):512-8. PubMed ID: 6164816
    [No Abstract]   [Full Text] [Related]  

  • 12. [Properties of cyclic nucleotide phosphodiesterase from lingual taste papillae].
    Ostretsova IB
    Biokhimiia; 1978 Jun; 43(6):1037-44. PubMed ID: 27246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
    Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
    J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
    Murray KJ; England PJ
    Biochem Soc Trans; 1992 May; 20(2):460-4. PubMed ID: 1327922
    [No Abstract]   [Full Text] [Related]  

  • 15. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
    Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation.
    Rybalkin SD; Bornfeldt KE
    Thromb Haemost; 1999 Aug; 82(2):424-34. PubMed ID: 10605733
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G; Prigent AF
    Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma.
    Nicholson CD; Shahid M
    Pulm Pharmacol; 1994 Feb; 7(1):1-17. PubMed ID: 8003849
    [No Abstract]   [Full Text] [Related]  

  • 19. Myofibrillar bound cyclic nucleotide phosphodiesterase in heart and skeletal muscle.
    Worby A; Mensah LM; Murray KJ
    Biochem Soc Trans; 1992 May; 20(2):129S. PubMed ID: 1327896
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclic nucleotide phosphodiesterase of normal and leukemic lymphocytes. Kinetic properties and selective alteration of the activity of the multiple molecular forms.
    Hait WN; Weiss B
    Mol Pharmacol; 1979 Nov; 16(3):851-64. PubMed ID: 231197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.